FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

OSI looks to unload Macugen, exit eye diseases

Just a year after buying Macugen from Eyetech  (a 2003 Fierce 15 company), OSI Pharmaceuticals is looking for a way out of the eye disease sector. The company reports that it is exploring licensing or selling Macugen and its research assets in the field. Analysts expect OSI to shift its attention to its pipeline, which includes a promising therapy for diabetes. Analysts never did like the Macugen deal, which came as Genentech was on the verge of an approval for Lucentis to fight age-related macular degeneration. Lucentis and off-label injections of Avastin have quickly claimed a major share of the business.

- read the report on OSI from The Los Angeles Times

Related Article:
Lucentis gets the green light from regulators. Report

More stories about Genentech   age related macular degeneration   Lucentis   Eyetech   Regulators   Diabetes   pipeline   Macugen   OSI Pharmaceuticals   Avastin  

Comments

Give diabetes research money.
diabetes is an apidemic. Everyone has diabetes lately. Any thing that helps diabetics helps everyone else stay lose weight.

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 4 + 20?
To combat spam, please solve the math question above.